Actavis becomes Allergan and looks to manufacturing for cutting costs

Actavis ($ACT) has completed its $66 billion buyout of Allergan, which has implications for the manufacturing networks of the two companies. Actavis, which will take on the Allergan name, has said that it expects to find "$1.8 billion in operating and financial synergies" in the first year, and that those "exclude any additional revenue or manufacturing synergies." Actavis alone has more than 30 manufacturing and distribution facilities around the world, while Allergan, according to an SEC filing, has 8 manufacturing facilities that it owns or leases. Release | More from FiercePharma

Suggested Articles

Cambrex has completed installation of multiple continuous flow reactor platforms at its facility in High Point, North Carolina.

Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.

GE is launching its prefab line of drug manufacturing units that will help biopharma companies produce viral vector-based vaccines.